Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species

Jérôme Alexandre1, Yumin Hu, Weiqin Lu

  • 1Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA.

Cancer Research
|April 19, 2007
PubMed

Insights

Paclitaxel generates extracellular reactive oxygen species (ROS) via NADPH oxidase, causing lethal damage to nearby cancer cells. This novel bystander effect enhances paclitaxel

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Paclitaxel induces reactive oxygen species (ROS) in cancer cells, but mechanisms and implications are unclear.
  • Extracellular ROS generation by paclitaxel has not been previously characterized.

Purpose of the Study:

  • To elucidate the mechanism of paclitaxel-induced ROS generation.
  • To investigate the therapeutic implications of paclitaxel-induced extracellular ROS.
  • To determine if paclitaxel induces a cytotoxic bystander effect.

Main Methods:

  • Investigated paclitaxel's effect on NADPH oxidase (NOX) activity and Rac1 translocation in breast cancer cells.
  • Quantified extracellular and intracellular ROS (O2(-) and H2O2) using fluorescent and radioactive labeling in coculture systems.
  • Assessed the role of superoxide dismutase (SOD) and catalase in mediating the bystander effect.
  • Evaluated the impact of paclitaxel on bystander cell proliferation.

Main Results:

  • Paclitaxel rapidly enhanced plasma membrane-associated NOX activity, increasing extracellular O2(-) and H2O2.
  • Rac1 translocation to the plasma membrane was increased by paclitaxel treatment.
  • Extracellular ROS generated by paclitaxel induced lethal damage and inhibited proliferation in bystander cancer cells.
  • This cytotoxic bystander effect was observed with other microtubule-targeting agents but not with 5-fluorouracil or doxorubicin.

Conclusions:

  • Paclitaxel induces a novel cytotoxic bystander effect through extracellular ROS generated by membrane-associated NOX.
  • This mechanism contributes to paclitaxel's anticancer activity and suggests new therapeutic strategies.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...